Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer

  • NREC Code:

    22-NREC-CT-018

  • Decision:

    Favourable

  • Meeting Date:

    09/02/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Dearbhaile Collins

  • Sponsor:

    MSD

Scroll to Top